ECSP14000329A - Moléculas que son anticuerpos con especificidad por ox40 humano - Google Patents

Moléculas que son anticuerpos con especificidad por ox40 humano

Info

Publication number
ECSP14000329A
ECSP14000329A ECIEPI2014329A ECPI201400329A ECSP14000329A EC SP14000329 A ECSP14000329 A EC SP14000329A EC IEPI2014329 A ECIEPI2014329 A EC IEPI2014329A EC PI201400329 A ECPI201400329 A EC PI201400329A EC SP14000329 A ECSP14000329 A EC SP14000329A
Authority
EC
Ecuador
Prior art keywords
antibodies
molecules
specificity
human
producing
Prior art date
Application number
ECIEPI2014329A
Other languages
English (en)
Inventor
Inc A Delaware Corporation Eyeverify
Sanofi
Paolo Figli S P A Ballarini
Original Assignee
Dolivar Coraucci Neto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47388492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14000329(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dolivar Coraucci Neto filed Critical Dolivar Coraucci Neto
Publication of ECSP14000329A publication Critical patent/ECSP14000329A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a moléculas que son anticuerpos con especificidad por determinantes antigénicos de OX40 humano, a usos terapéuticos de las moléculas que son anticuerpos y a métodos para producir dichas moléculas que son anticuerpos.
ECIEPI2014329A 2011-11-11 2014-05-08 Moléculas que son anticuerpos con especificidad por ox40 humano ECSP14000329A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161558545P 2011-11-11 2011-11-11

Publications (1)

Publication Number Publication Date
ECSP14000329A true ECSP14000329A (es) 2016-01-29

Family

ID=47388492

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI2014329A ECSP14000329A (es) 2011-11-11 2014-05-08 Moléculas que son anticuerpos con especificidad por ox40 humano

Country Status (35)

Country Link
US (2) US9040048B2 (es)
EP (1) EP2776469B1 (es)
JP (1) JP6367714B2 (es)
KR (1) KR102071054B1 (es)
CN (1) CN103946240B (es)
AP (1) AP2014007668A0 (es)
AR (1) AR088820A1 (es)
AU (1) AU2012333997B2 (es)
BR (1) BR112014011404A2 (es)
CA (1) CA2855174C (es)
CL (1) CL2014001193A1 (es)
CO (1) CO7010784A2 (es)
CY (1) CY1122073T1 (es)
DK (1) DK2776469T3 (es)
EA (1) EA035112B1 (es)
EC (1) ECSP14000329A (es)
ES (1) ES2737998T3 (es)
HR (1) HRP20191219T1 (es)
HU (1) HUE044333T2 (es)
IL (1) IL232420B (es)
LT (1) LT2776469T (es)
MA (1) MA35724B1 (es)
MX (1) MX358391B (es)
MY (1) MY183795A (es)
PE (1) PE20141995A1 (es)
PH (1) PH12014500946A1 (es)
PL (1) PL2776469T3 (es)
PT (1) PT2776469T (es)
SG (1) SG11201402093RA (es)
SI (1) SI2776469T1 (es)
TN (1) TN2014000206A1 (es)
TR (1) TR201910721T4 (es)
TW (1) TWI588155B (es)
UA (1) UA112203C2 (es)
WO (1) WO2013068563A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398498B1 (en) * 2009-02-17 2018-09-05 UCB Biopharma SPRL Antibody molecules having specificity for human ox40
ES2667258T3 (es) * 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
PL2609118T3 (pl) 2010-08-23 2017-07-31 Board Of Regents, The University Of Texas System Przeciwciała anty-OX40 i sposoby ich stosowania
US10752676B2 (en) * 2011-09-16 2020-08-25 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
NZ712903A (en) 2013-03-18 2018-07-27 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
WO2015041515A1 (en) 2013-09-19 2015-03-26 N.V. Nutricia Improved process for the humanization of animal skim milk
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
HRP20230046T1 (hr) 2015-03-03 2023-03-03 Kymab Limited Protutijela, upotreba i postupci
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
PH12017502013B1 (en) * 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
MA43017A (fr) * 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
CN108137684B (zh) * 2015-10-15 2022-03-08 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
CA3006963A1 (en) * 2015-12-03 2017-06-08 Ludwig Institute For Cancer Research Ltd. Anti-ox40 antibodies and methods of use thereof
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US12296285B2 (en) 2019-08-02 2025-05-13 UCB Biopharma SRL Methods for purifying antibodies
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2025248017A1 (en) 2024-05-31 2025-12-04 UCB Biopharma SRL Method of purifying recombinant proteins

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US7850965B2 (en) 2005-12-05 2010-12-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
WO2007112054A2 (en) 2006-03-23 2007-10-04 Sea Lane Biotechnologies, Llc Facilitation of translocation of molecules through the gastrointestinal tract
CA2679399A1 (en) 2007-02-27 2008-09-04 Genetech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
LT2334705T (lt) * 2008-09-26 2017-03-27 Ucb Biopharma Sprl Biologiniai produktai
EP2398498B1 (en) 2009-02-17 2018-09-05 UCB Biopharma SPRL Antibody molecules having specificity for human ox40
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
JP5522668B2 (ja) 2010-02-03 2014-06-18 株式会社ブリヂストン タイヤ構成部材の切断装置及び製造方法
SI2776466T1 (sl) * 2011-11-11 2017-12-29 Ucb Biopharma Sprl Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti

Also Published As

Publication number Publication date
EA201400565A1 (ru) 2014-12-30
EA035112B1 (ru) 2020-04-28
PL2776469T3 (pl) 2019-10-31
LT2776469T (lt) 2019-08-12
KR20140097329A (ko) 2014-08-06
CA2855174C (en) 2021-11-02
CL2014001193A1 (es) 2014-12-26
WO2013068563A3 (en) 2013-06-27
HRP20191219T1 (hr) 2019-10-04
KR102071054B1 (ko) 2020-01-29
PE20141995A1 (es) 2014-12-06
HUE044333T2 (hu) 2019-10-28
SG11201402093RA (en) 2014-06-27
WO2013068563A9 (en) 2014-06-19
US20130243772A1 (en) 2013-09-19
EP2776469A2 (en) 2014-09-17
AU2012333997A1 (en) 2014-05-29
CN103946240A (zh) 2014-07-23
CN103946240B (zh) 2018-02-23
BR112014011404A2 (pt) 2017-05-30
IL232420B (en) 2019-02-28
DK2776469T3 (da) 2019-07-29
NZ624583A (en) 2015-05-29
MA35724B1 (fr) 2014-12-01
US9040048B2 (en) 2015-05-26
SI2776469T1 (sl) 2019-09-30
TWI588155B (zh) 2017-06-21
AU2012333997B2 (en) 2017-08-31
MX2014005564A (es) 2014-11-10
MX358391B (es) 2018-08-17
ES2737998T3 (es) 2020-01-17
TN2014000206A1 (en) 2015-09-30
AP2014007668A0 (en) 2014-05-31
TR201910721T4 (tr) 2019-08-21
AR088820A1 (es) 2014-07-10
UA112203C2 (uk) 2016-08-10
CA2855174A1 (en) 2013-05-16
IL232420A0 (en) 2014-06-30
WO2013068563A2 (en) 2013-05-16
PH12014500946A1 (en) 2014-06-09
PT2776469T (pt) 2019-07-25
EP2776469B1 (en) 2019-04-24
MY183795A (en) 2021-03-16
JP6367714B2 (ja) 2018-08-01
JP2015506910A (ja) 2015-03-05
TW201326205A (zh) 2013-07-01
CO7010784A2 (es) 2014-07-31
CY1122073T1 (el) 2020-11-25
US9873735B2 (en) 2018-01-23
US20160031974A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
UY32451A (es) Moléculas de anticuerpo con especifidad por el ox40 humano
UY32489A (es) Moléculas de anticuerpos que tienen especificidad de unión por il-13 humana
CO6781516A2 (es) Moléculas de anticuerpos que se unen a il-17a y il-17f
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
AR061538A1 (es) Moleculas de anticuerpo que se unen a la il-17 humana
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
ECSP17041865A (es) Anticuerpos anti-cd47 y usos de los mismos
NI201400061A (es) Anticuerpos anti - phf - tau y sus usos
ECSP13012859A (es) Anticuerpos del cea
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
ECSP088613A (es) Moléculas de anticuerpo que tienen especificidad para la il-6 humana
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
MX2023006416A (es) Anticuerpos, usos y metodos.
MX2015008117A (es) Anticuerpos anti-h7cr.
UY34679A (es) ?PROCEDIMIENTO PARA OBTENER UNA COMPOSICIÓN DE IgG MEDIANTE TRATAMIENTO TÉRMICO?
CL2022001684A1 (es) Anticuerpo con especificidad de unión para il-13 humana
BR112018011862A2 (pt) moléculas de anticorpo que ligam tnf alfa